Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2025-12-26 @ 2:04 AM
Study NCT ID:
NCT05272605
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2022-03-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Sponsor:
University of Melbourne
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-05
Start Date Type:
ACTUAL
Primary Completion Date:
2023-04-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-04-19
Completion Date Type:
ACTUAL
First Submit Date:
2022-03-03
First Submit QC Date:
None
Study First Post Date:
2022-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-12
Last Update Post Date:
2023-05-15
Last Update Post Date Type:
ACTUAL